Rubeosis iridis.
Pagoulatos D, Georgakopoulos C.
Pan Afr Med J. 2017 Nov 29;28:279. doi: 10.11604/pamj.2017.28.279.13717. eCollection 2017.
Neovascular Glaucoma.
Mishra C, Meyer JJ.
2022 Nov 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy.
Weng SW, Huang TL, Su PY, Chang PY, Wang JK.
Eye Sci. 2015 Dec;30(4):201-3.
Neovascularization of the iris (rubeosis iridis).
Gartner S, Henkind P.
Surv Ophthalmol. 1978 Mar-Apr;22(5):291-312. doi: 10.1016/0039-6257(78)90175-3.
Rubeosis iridis.
McGARRY HI.
Am J Ophthalmol. 1946 Dec;29(12):1590.
Fluorescein angiography of extreme peripheral retina and rubeosis iridis in proliferative diabetic retinopathy.
Terasaki H, Miyake Y, Mori M, Suzuki T, Kondo M.
Retina. 1999;19(4):302-8. doi: 10.1097/00006982-199907000-00006.
Rubeosis iridis after vitrectomy for diabetic retinopathy.
Helbig H, Kellner U, Bornfeld N, Foerster MH.
Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):730-3. doi: 10.1007/s004170050150.
Rubeosis iridis.
Anderson DM, Morin JD, Hunter WS.
Can J Ophthalmol. 1971 Jul;6(3):183-8.
The frequency of rubeosis iridis in diabetic patients.
Ohrt V.
Acta Ophthalmol (Copenh). 1971;49(2):301-7. doi: 10.1111/j.1755-3768.1971.tb00954.x.
Development and classification of rubeosis iridis in diabetic eye disease.
Laatikainen L.
Br J Ophthalmol. 1979 Mar;63(3):150-6. doi: 10.1136/bjo.63.3.150.
